These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 33065647)

  • 1. Comments on "Importance of Normalization of CA19-9 Levels After Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer".
    Xu HX; Li S; Xu SS; Liu L; Yu XJ
    Ann Surg; 2021 Dec; 274(6):e800-e801. PubMed ID: 33065647
    [No Abstract]   [Full Text] [Related]  

  • 2. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer.
    Tsai S; George B; Wittmann D; Ritch PS; Krepline AN; Aldakkak M; Barnes CA; Christians KK; Dua K; Griffin M; Hagen C; Hall WA; Erickson BA; Evans DB
    Ann Surg; 2020 Apr; 271(4):740-747. PubMed ID: 30312198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis.
    Ye C; Sadula A; Ren S; Guo X; Yuan M; Yuan C; Xiu D
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):731-740. PubMed ID: 33047181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
    Aoki S; Motoi F; Murakami Y; Sho M; Satoi S; Honda G; Uemura K; Okada KI; Matsumoto I; Nagai M; Yanagimoto H; Kurata M; Fukumoto T; Mizuma M; Yamaue H; Unno M;
    BMC Cancer; 2019 Mar; 19(1):252. PubMed ID: 30898101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer.
    Aldakkak M; Christians KK; Krepline AN; George B; Ritch PS; Erickson BA; Johnston FM; Evans DB; Tsai S
    HPB (Oxford); 2015 Oct; 17(10):942-52. PubMed ID: 26255895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant therapy for pancreatic cancer: an intention-to-treat analysis.
    Okada K; Murakami Y; Uemura K; Kondo N; Nakagawa N; Seo S; Otsuka H; Takahashi S
    Langenbecks Arch Surg; 2020 Aug; 405(5):623-633. PubMed ID: 32592044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer.
    Miura JT; Krepline AN; George B; Ritch PS; Erickson BA; Johnston FM; Oshima K; Christians KK; Evans DB; Tsai S
    Surgery; 2015 Dec; 158(6):1545-55. PubMed ID: 26243342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASO Author Reflections: Does Adjuvant Therapy Confer a Survival Benefit in Patients Receiving Neoadjuvant Chemotherapy for Pancreatic Cancer? A CA19-9 Analysis.
    Liu H; Zureikat A
    Ann Surg Oncol; 2020 Oct; 27(10):3961-3962. PubMed ID: 32372314
    [No Abstract]   [Full Text] [Related]  

  • 9. ASO Author Reflections: Serum CA19-9 Utility in Pancreatic Adenocarcinoma in Patients Undergoing Neoadjuvant Therapy.
    Al Abbas AI; Hogg ME
    Ann Surg Oncol; 2020 Jun; 27(6):2015-2016. PubMed ID: 32172332
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.
    Tzeng CW; Balachandran A; Ahmad M; Lee JE; Krishnan S; Wang H; Crane CH; Wolff RA; Varadhachary GR; Pisters PW; Aloia TA; Vauthey JN; Fleming JB; Katz MH
    HPB (Oxford); 2014 May; 16(5):430-8. PubMed ID: 23991810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy.
    van Veldhuisen E; Vogel JA; Klompmaker S; Busch OR; van Laarhoven HWM; van Lienden KP; Wilmink JW; Marsman HA; Besselink MG
    HPB (Oxford); 2018 Jul; 20(7):605-611. PubMed ID: 29475787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
    Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
    J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten-year experience in optimizing neoadjuvant therapy for localized pancreatic cancer-Medical college of Wisconsin perspective.
    Ward EP; Evans DB; Tsai S
    J Surg Oncol; 2021 May; 123(6):1405-1413. PubMed ID: 33831252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Advances in Localized Pancreatic Cancer.
    Tsai S; Evans DB
    JAMA Surg; 2016 Sep; 151(9):862-8. PubMed ID: 27276001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
    Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
    J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
    Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
    Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease.
    Abdel-Misih SR; Hatzaras I; Schmidt C; Saab TB; Klemanski D; Muscarella P; Melvin WS; Ellison EC; Bloomston M
    Ann Surg Oncol; 2011 Apr; 18(4):1116-21. PubMed ID: 21042945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real world outcomes of neoadjuvant chemotherapy and radiotherapy for borderline resectable pancreatic cancer: a multicentre observational study.
    Parsonson AO; Connolly E; Lee M; Hruby G; Sandroussi C; Merrett N; Samra J; Mittal A; Tse R; Grimison P
    ANZ J Surg; 2021 Nov; 91(11):2447-2452. PubMed ID: 34427029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
    Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
    Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Predicting value of serum CEA and CA19-9 in neoadjuvant chemotherapy for advanced gastric carcinoma].
    Wang JH; Mai C; Hong J; Zhang Q; Tang HS; Tang YQ; Cui SZ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Dec; 15(12):1273-6. PubMed ID: 23268276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.